OncoPharm

Ribociclib-Tamoxifen: A Cautionary Tale by John Bossaer

Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.

Open up your Yelp app and check out Leukemia Pharmacist & Boston denizen Jessie Signorelli's recommendations for eating, drinking, & sight seeing in Boston. Also, great educational programming awaits!

Trastuzumab deruxtecan vs. trastuzumab trastuzumab

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

Delve into the fascinating origins of Acute Myelogenous Leukemia treatment with a look back at pivotal studies and key clinical trials. Discover the impactful evolution of the 7 plus 3 chemotherapy regimen that revolutionized AML therapy since the 1970s. The conversation also breezes through nostalgic references to 1975 films, weaving together a mix of historical insights and contemporary relevance in cancer treatment.

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.

Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/

This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0 Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187